Arthur Kuan, CG Oncology CEO
CG Oncology reels in $105M crossover for potential late 2024 bladder cancer drug filing
CG Oncology, out to treat bladder cancer patients left behind by the shortage of Merck’s standard BCG therapy or didn’t benefit from it in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
